1. Use of a therapeutically effective amount lahinimoda or a pharmaceutically acceptable salt thereof for producing a medicament for treating a subject having an inflammatory eye disease and / or inflammation of the eye associated with autoimmune zabolevaniem.2. Use according to Claim. 1, wherein the therapeutically effective amount lahinimoda effective for ameliorating the symptoms of inflammatory diseases of the eye of the subject, it causes clinical response, causes or maintains clinical remission, inhibits the progression of the disease, suppresses complication of the disease, reduces intraocular inflammation or attenuates retinal tissue destruction in subekta.3 . Use according to Claim. 1 or 2, wherein the inflammatory eye disease is uveitis, bacterial conjunctivitis, viral conjunctivitis, ophthalmic inflammation or tissue lacrimal apparatus century, cornea, retina or optic putey.4. Use according to claim. 3, wherein the inflammatory eye disease is conjunctivitis and a therapeutically effective amount lahinimoda or a pharmaceutically acceptable salt thereof effective to alleviate the symptoms of conjunctivitis subekta.5. Use according to claim. 3, wherein the inflammatory eye disease is uveitis, and a therapeutically effective amount lahinimoda or a pharmaceutically acceptable salt thereof effective to alleviate the symptoms of uveitis subekta.6. Use according to claim. 5, wherein uveitis is anterior uveitis, intermediate uveitis, posterior uveitis or diffuse uveit.7. Use according to claim. 3, wherein the inflammatory eye disease is an inflammation of the ophthalmic tissues, lacrimal apparatus, eyelids, cornea, retina, and1. Применение терапевтически эффективного количества лахинимода или его фармацевтически приемлемой соли для получения лекарственного средства для лечения субъекта, страдающего воспалительным заболеванием глаз и/или воспалением глаз, связанным с аутоиммунным заболеванием.2. Применение по п. 1, где терапевтически эффективное количество лахинимо
